Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update NASHVILLE, TENNESSEE (Tuesday, May 7, 2024) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with$82 million in total assets, $54 million in total liabilities and$27 million of shareholders’ equity. “It has bee ...